GlassScriptPhysician profile
James J Ko
NPI 1376076786
$4,528.23
in general payments reported to CMS, 2019-2025
23 companies · $749 in 2025
The $749 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $622 · 2020: $199 · 2021: $322 · 2022: $266 · 2023: $1,363 · 2024: $1,008 · 2025: $749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,754 · Education: $366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,753.51 |
| Education | $365.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,190.47 | 2019-2025 | |
| Janssen Biotech, INC. | $731.41 | 2022-2025 | Tremfya, Stelara, Simponi |
| Regeneron Healthcare Solutions, INC. | $465.37 | 2019-2024 | Dupixent |
| Sun Pharmaceutical Industries INC. | $272.67 | 2022-2025 | Ilumya, Winlevi, Absorica Ld |
| Allergan, INC. | $259.57 | 2019-2020 | |
| Genzyme Corporation | $177.82 | 2023-2025 | |
| Lilly USA, LLC | $173.14 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $156.62 | 2024-2025 | Bimzelx |
| Amgen INC. | $129.62 | 2023-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $127.34 | 2023-2025 | |
| Galderma Laboratories, L.P. | $115.34 | 2023-2025 | Nemluvio, Aklief |
| Incyte Corporation | $110.13 | 2023-2025 | Opzelura |
| Pfizer INC. | $90.13 | 2023-2024 | |
| Arcutis Biotherapeutics, INC. | $85.85 | 2023-2024 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.22 | 2023-2024 | Spevigo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $67.44 | 2024-2025 | Seysara, Klisyri |
| E.R. Squibb & Sons, L.L.C. | $64.46 | 2023 | Sotyktu |
| Dermavant Sciences, INC. | $56.53 | 2023-2024 | Vtama |
| Verrica Pharmaceuticals INC. | $46.74 | 2024-2025 | Ycanth |
| Journey Medical Corporation | $45.01 | 2022-2024 | |
| Leo Pharma INC. | $41.31 | 2023 | Adbry |
| Botanix Sb INC | $23.94 | 2025 | Sofdra |
| Organon LLC | $20.10 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.